Rivoglitazone (INN) is a thiazolidinedione derivative undergoing research for use in the treatment of type 2 diabetes.[1][2]
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
ChEMBL |
|
Chemical and physical data | |
Formula | C20H19N3O4S |
Molar mass | 397.45 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(verify) |
It is being developed by Daiichi Sankyo.